For Patients on Hydroxychloroquine or Chloroquine
The Royal College of Ophthalmologists recommends annual monitoring for retinal toxicity for patients on long-term therapy of Hydroxychloroquine and Chloroquine. This service allows for primary care monitoring of patients within optical practice.
LOCSU’s pathway and clinical management guidelines offer an integrated service delivery model with data collection in primary care and virtual review by a consultant ophthalmologist. Aligning to the RCOphth guidelines, this allows for patients to be seen within the community in a consultant-led service.
The service aims to identify patients at risk of vision loss through monitoring.
LOCSU has developed a range of downloadable support for members of Local Optical Committees who want to introduce these pathways in their area.
Other Useful Documents
- Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening – Royal College of Ophthalmologists guidance
- Patient Leaflet – Eye Screening for Patients taking Hydroxychloroquine – Macular Society, Royal College of Ophthalmologists